# Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

> **NCT04828486** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 14 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- BCLC Stage A Hepatocellular Carcinoma
- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma

## Interventions

- **DRUG:** Futibatinib
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT04828486
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-17
- **Primary completion:** 2024-09-18
- **Final completion:** 2025-08-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04828486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04828486, "Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04828486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*